Login to Your Account



FDA Approves Herceptin In Adjuvant Breast Cancer

By Aaron Lorenzo


Monday, November 20, 2006
The FDA granted a broader label to Herceptin (trastuzumab), paving the way for Genentech Inc. to promote its most visible targeted oncology product as a front-line treatment for breast cancer.(BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription